Company Description
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally.
It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
It sells its products through the company’s web stores, third-party online retailers and distribution partners.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
| Country | United States |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Justin M. Hall Esq. |
Contact Details
Address: 2000 Powell Street, Suite 1150 Emeryville, California 94608 United States | |
| Phone | (510) 899-8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P3001 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin M. Hall Esq. | President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary and Director |
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 11, 2024 | FWP | Free Writing Prospectus |
| Jul 11, 2024 | 8-K | Current Report |
| Jul 10, 2024 | FWP | Free Writing Prospectus |
| Jul 10, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 28, 2024 | 424B3 | Prospectus |
| Jun 28, 2024 | D | Notice of Exempt Offering of Securities |
| Jun 27, 2024 | EFFECT | Notice of Effectiveness |
| Jun 21, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |